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Absence of the mouse cell surface receptor SLAMF3 in SLAMF3-/- mice suggested that
this receptor negatively regulates B cell homeostasis by modulating activation thresholds
of B cell subsets. Here, we examine whether anti-SLAMF3 affects both B and T cell
subsets during immune responses to haptenated ovalbumin [NP-OVA] and in the setting
of chronic graft vs. host disease (cGVHD) induced by transferring B6.C-H2bm12/KhEg
(bm12) CD4+ T cells into B6 WT mice. We find that administering αSLAMF3 to NP-OVA
immunized B6 mice primarily impairs antibody responses and Germinal center B cell
[GC B] numbers, whilst CXCR5+, PD-1+, and ICOS+ T follicular helper (TFH) cells
are not significantly affected. By contrast, administering αSLAMF3 markedly enhanced
autoantibody production upon induction of cGVHD by the transfer of bm12 CD4+ T
cells into B6 recipients. Surprisingly, αSLAMF3 accelerated both the differentiation of
GC B and donor-derived TFH cells initiated by cGVHD. The latter appeared to be
induced by decreased numbers of donor-derived Treg and T follicular regulatory (TFR)
cells. Collectively, these data show that control of anti-SLAMF3-induced signaling is
requisite to prevent autoantibody responses during cGVHD, but reduces responses to
foreign antigens.
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INTRODUCTION
The signaling lymphocyte activation molecule family (SLAMF) of cell surface receptors, which
consists of nine trans-membrane proteins (SLAMF1-9) serve as co-stimulatory molecules at
immune synapses, are involved in viral and bacterial recognition and modulate myeloid and
lymphocyte development (1). We previously found that the homophilic receptor SLAMF6 (Ly108,
NTB-A) is implicated in the Germinal Center Reaction and that monoclonal antibodies directed
against SLAMF6 reduce antibody responses to foreign antigens (Ags) and affect the number of
auto-reactive B cells (2, 3). SLAMF3 (CD229. Ly9) is also localized at the interface between the
immune synapse, suggesting a role for SLAMF3 in regulating humoral immune responses (1, 4).
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Our studies with SLAMF3 deficient mice demonstrated that
transitional 1, MZ, and B1a B cells were markedly expanded,
whereas the development of conventional B-lymphocytes was
unaltered (5). As MZ and B1 B cells respond to foreign Ags
more rapidly than conventional B cells, elevated levels of IgG3
natural Abs were found in the serum of SLAMF3-deficient mice.
Furthermore, a striking increase of T-independent Abs after
immunization with 2,4,6-trinitrophenyl-Ficoll was found (5).
Administering a mouse monoclonal antibody (mAb) directed
against murine SLAMF3 (αSLAMF3) selectively eliminated
splenic MZ B cells and significantly reduced the numbers of
B1 and transitional 1 B cells in wild-type mice. Surprisingly,
administering an agonistic anti-SLAMF3 mAb (Ly9.7.144)
diminished both T cell-dependent and –independent antibody
responses indicating a role for SLAMF3 dependent signaling
in negative regulation of humoral immune responses. Anti-
SLAMF3 (Fab’)2 has a similar effect, which excludes Fc dependent
effector mechanisms. The concept of SLAMF3 as negative
regulator of antibody responses was further supported by the
finding that aged SLAMF3-deficientmice developed spontaneous
autoantibodies against nuclear antigens (5, 6).
Here, we examine whether αSLAMF3 affects both B and T
cell subsets during immune responses to haptenated ovalbumin
[NP-OVA] and in the setting of chronic graft vs. host disease
(cGVHD) induced by transferring B6.C-H2bm12/ KhEg (bm12)
CD4+ T cells into B6WTmice (7–9). We find that administering
a single dose of αSLAMF3 to NP-OVA immunized B6 mice
primarily impairs antibody responses and Germinal center
B (GC B) cell numbers, whilst CXCR5+PD-1+, and ICOS+
T follicular helper (TFH) cells are not significantly affected.
By contrast, two injections of αSLAMF3 markedly enhanced
autoantibody production upon induction of cGVHD by the
transfer of bm12 CD4+ T cells into B6 recipients (8, 9).
Surprisingly, αSLAMF3 accelerated both the differentiation of
GCB and donor-derived TFHs cell initiated by cGVHD. The
latter appeared to be induced by expansion of donor-derived
regulatory T (Treg) and T follicular regulatory (TFR) cells. Our
findings suggest that, SLAMF3 induced signaling plays a different
role in the setting of normal immune responses and in response
to autoantibody responses.
MATERIALS AND METHODS
Mice
C57BL/6 (B6) WT and B6.C-2bm12/KhEg (bm12) mice were
obtained from the Jackson Laboratory. B6.C-2bm12/KhEg (bm12)
x CD45.1 mice were generated by crossing B6.C-2bm12/KhEg
(bm12) with CD45.1.B6. Experiments were conducted using
age-matched 8–10 weeks old female mice. All animals are
maintained under specific pathogen-free conditions at the Beth
Israel Deaconess Medical Center (BIDMC) animal facility.
Experiments were performed according to the guidelines of
the Institutional Animal Care and Use Committee (IACUC)
at BIDMC.
Mouse Anti-SLAMF3 Antibody
Mouse anti-mouse SLAMF3 (SLAMF3.7.144) (IgG1 isotype)
monoclonal antibody was generated as described elsewhere (10).
NP-OVA Immunizations
NP-OVA immunizations and measurement of NP-specific
antibodies are described elsewhere (2). In short, WT mice were
immunized with 50 µg NP-OVA in Complete Freund’s Adjuvant
(CFA). At the same time, mice were injected with 250 µg/mouse
αSLAMF3 or mIgG1 isotype control. Immunized mice were
sacrificed on day 9. Cell subsets analyzed from splenocytes: TFH
cells: CD4+CXCR5+PD1+; GC B cells: B220+GL-7+FAS+.
cGVHD Induction by the Transfer of bm12
CD4+ T Cells Into B6 Mice
We adapted the bm12 transfer model, as originally described
by Morris et al. (9). Eight to ten weeks old B6 WT mice were
injected i.p. with 6 × 106 purified CD4+ T cells from bm12 or
bm12xCD45.1 mice.
For in vivo anti-SLAMF3 injections, recipients were injected
i.p.with 200µg of anti-SLAMF3 antibody or IgG1 isotype control
on days−1 and 14 after transfer of 3 × 106 bm12 CD4+ T cells
into B6.WT mice. Mice were sacrificed and analyzed on day 28.
Flow Cytometry
Single-cell suspensions were prepared from spleens using
standard procedures. After red blood cell (RBC) lysis (Sigma, St.
Louis, MO), single cell suspensions were obtained. Cells were
blocked with anti-CD16/32 Ab (2.4G2, Biolegend) and stained
in FACS staining buffer (2.5% FBS, 0.05% sodium azide in
PBS). The following antibodies were used: CD4 (L3T4), CD44
(IM7), CD62L (MEL-14, CD69 (H1.2F3), CD86 (GL-1), CD138
(281-1), B220 (RA3-6B2), CD19 (6D5), FAS (Jo2), T-and B-cell
activation antigen (GL-7), CXCR5 (2G8), and PD-1 (29F, 1A12)
were purchased from eBioscience (ThermoFisher, Cambridge,
MA), BD Biosciences (Woburn, MA), or Biolegend (San Diego,
CA). TFH cells were stained as previously described (2). Dead
cells were excluded with 4,6-Diamidino-2-phenylindole (DAPI).
Data were acquired on a BD LSR II cytometer and analyzed using
FlowJo software (Tree Star, Ashland, Oregon).
Intracellular Cytokine Staining
Cytokine production was assessed with BD Cytofix/Cytoperm
containing BD Golgi-Plug (BD Biosciences). Cells were
stimulated with phorbol 12-myristate 13-acetate (PMA,
50 ng/ml, Sigma), Ionomycin (1µg/ml, Sigma), and GolgiStop (1
µl/ml, BD Biosciences) at 37◦C in 5% CO2 for 4 h. After surface
staining, cells were fixed, permeabilized, and stained for IFN-γ
(PE-anti-mouse IFN-γ, Biolegend), IL-4 (PE-anti-mouse IL-4,
Biolegend), and IL-17 (PE-anti-mouse IL-17A, Biolegend). For
intracellular staining IL-21, permeabilized cells were incubated
with IL-21R/Fc chimera (R&D systems) for 1 h at 4◦C. Cells
were then washed and stained with PE-conjugated affinity-
purified F(ab’)2 fragment of goat anti-human Fc γ antibody
(Jackson ImmunoResearch Laboratories) for 30min at 4◦C.
Viability was assessed using LIVE/DEAD Cell Viability Assays
(Life Technologies).
ELISA
Titers of anti-nucleosome antibodies in the serum were
determined by ELISA as described previously (11, 12). In brief,
met-BSA-precoated Immunolon plated were coated overnight
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with double stranded DNA (dsDNA) and then with total histone
solution. Samples were incubated on plates in various dilutions
between 1:600 and 1:1,200, and then washed, and autoantibodies
were detected with anti-mouse IgG-HRPO (GE Healthcare).
Autoantibody titer was expressed as ELISA unit, comparing
OD values of samples with a standard curve prepared with
serial dilutions of ANA-positive NZM2410 serum pool. Anti-
chromatin and anti-dsDNA titers were determined as for
the anti-nucleosome levels. UV-irradiated Immunolon plates
were incubated overnight with 3µg/ml chicken chromatin (13)
or mung bean nuclease (New England Biolabs, Ins.)-treated
dsDNA (Sigma-Aldrich. Anti-single-strandedDNA (ssDNA) was
determined as describe previously (14).
Statistical Analysis
Statistical significance was determined by unpaired t-test (two-
tailed with equal SD) using Prism software (GraphPad,
San Diego, CA, USA). The p < 0.05 was considered
statistically significant.
RESULTS
Administering αSLAMF3 Reduces GC B
Cell Formation and Antibody Resposes
to NP-ovalbumn
To assess which cell types are affected by αSLAMF3 we
immunized B6. WT mice with NP-OVA in conjunction with
injecting αSLAMF3 or an isotype control. On day 9 we found
no difference in spleen weight or total number of splenocytes
between isotype and αSLAMF3 injected groups (Figure S1). As
expected from a preliminary study (6), we found significantly
reduced levels of NP-specific antibodies in the serum of
αSLAMF3 injected groups as compared to isotype-injected mice
(Figure 1A). Further analysis revealed a significant reduction in
total B cells and MZ B cells (Figure 1B and Figure S1), but more
importantly dramatically reduced percentage and numbers of
GC B cells in spleen of αSLAMF3 injected mice (Figure 1C).
However, no difference in total CD4+ T cells or TFH cells was
found (Figure 1D and Figure S1), suggesting that the antibody
primarily affects B cells in this system. While this was in
the case of co-injection of αSLAMF3 together with NP-OVA
immunization, injection of antibody at a later time point (day
4) showed similar results (Figure S2), demonstrating that our
findings are independent of time of injection.
Administering αSLAMF3 Enhances
Autoantibody Production Upon Induction
of cGVHD by the Transfer of bm12 CD4+ T
Cells Into B6 Recipients
Our previous studies demonstrated that spontaneous anti-
nuclear antibody (ANA) production in SLAMF3-/- mice
was independent of the background (B6.129 or Balb/c.129),
suggesting that SLAMF3may play an important role in regulating
autoimmunity (6). These findings led us to investigate the
consequences of modulating SLAMF3 during autoimmune
responses using a monoclonal mouse anti-SLAMF3 antibody
(αSLAMF3). In addition to initiating cGVHD, 200 µg/mouse
αSLAMF3 or isotype control was i.p. injected into bm12
mice−1 and 14 days after transfer of B6.WT donor CD4+
T cells. Mice were euthanized and analyzed 28 days after
transfer. Mice injected with αSLAMF3 had significantly bigger
spleen size, weight and total number of splenocytes compared
to isotype control (Figure S3). The levels of anti-chromatin,
anti-single-stranded DNA (ssDNA) and double-stranded DNA
(dsDNA) were substantially increased in the serum of mice
that had received αSLAMF3 as compared to isotype control
(Figures 2A–C). Percentage and numbers of marginal zone B
cells decreased while total number of B cells in the spleen
remained unchanged (Figure S3). Consistent with the increase
in autoantibody production, the percentage of plasma cells was
significantly expanded in the spleen of αSLAMF3-injected mice
(Figure 2D). To further validate these observations, lymphoid
follicles and GCs of recipient mice were measured with
immunofluorescence staining from frozen spleen sections. B cell
zones were identified by B220 and GC area was marked by GL7+
zone surrounded by IgD+ naive B cells. This showed that the
size of Germinal Centers was increased in B6 recipients that
had received two injections of anti-SLAMF3 (Figure 2E). Similar
results were obtained with 4 injections of αSLAMF3 in bm12
CD4+ T cell transfers and αSLAMF1 was used as a control
(see Figure S5). Anti-SLAMF3 injected group had significantly
higher percentages of GC B cells and increased autoantibody
production, whereas αSLAMF1 did not promote autoantibody
production (Figures S5, S6).
Anti-SLAMF3 Accelerates GC B Cell
Differentiation Initiated by cGVHD
Selection, isotype switching and expansion of GC B cells
require critical signals from T follicular helper (TFH) cells.
During chronic GVHD autoantibodies are produced due to the
generation of autoimmune TFH and GC B cells in response to
the donor CD4+ T cells (9). To assess whether the increased
autoantibody production inmice injected with αSLAMF3was the
consequence of modulating the GC reaction, we first examined
the presence of GC B cells in the spleen of recipient mice, 14 days
post transfer of bm12 CD4+ T cells. In keeping with enhanced
GC formation, the expression of CD86 and the proportion of
CD69 activated B cells were markedly increased in anti-SLAMF3
injected recipients (Figures 3A,B). Surprisingly, the expression
of FAS was not only increased on the surface of GC B cells,
but also on all B cells (Figure 3C). As expected, flow cytometry
analyses revealed a significant expansion of the percentage and
number of CD19+FAS+GL-7+ GC B cells in αSLAMF3-injected
recipients as compared to isotype control (Figures 3D,E).
Previous studies have indicated a key role for the IFN-γ
receptor (IFN-γR) in development of autoantibody production
in lupus-prone mice, e.g., MRL/Lpr, NZB/W, B6.Sle1b, and
Roquin san/san (15–18). Deletion of IFN-γR on B cells abrogates
formation of autoimmune GCs and autoimmunity (19). Based
on these observations, we examined the surface expression of
IFN-γR on GC B cells from recipients of bm12 CD4+ T cells.
In parallel with the enhanced GC formation, administration
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FIGURE 1 | Administering αSLAMF3 to NP-OVA immunized B6 WT mice reduces B cell numbers and antibody responses. WT mice were immunized with NP-OVA in
CFA along with 200 µg/mouse αSLAMF3 or isotype IgG1. Nine days later mice were euthanized and spleens were analyzed. (A) NP-specific antibody titers from
serum of αSLAMF3 and isotype injected mice are as shown. (B) Total number of splenocytes from αSLAMF3 and isotype injected mice. (C) Representative Flow
cytometry plots for GC staining: CD19+GL-7+FAS+ B cells (left), percentage and numbers of GC B cells (right). (D) Representative Flow cytometry plot showing
gating strategy for TFH cells: CD4+PD-1+CXCR5+ (left panel) Percentages and numbers of TFH cells in spleen of αSLAMF3 and isotype injected mice (right panel).
Data representative of three independent experiments. P-values are as shown.
of αSLAMF3 markedly increased percentage of IFN-γR+ GC
B cells, compared to recipients that received isotype control
(Figures 3F,G). These findings suggest that SLAMF3 indeed
enhances the expansion of autoreactive GC B cells and that
the αSLAMF3 antibody positively affects this cGVHD driven-
expansion.
Administering αSLAMF3 Increases T Cell
Activation and TFH Cell Differentiation
Initiated by cGVHD
As the cGVHD in B6 recipients is initiated and driven by
the transfer of bm12 co-isogenic CD4+ T cells we further
analyzed the T cell compartment. As judged by expression
of CD44, CD62, and CD69, the percentage and number of
effector CD4+ T cell were also higher in αSLAMF3 treated
recipients (Figures 4A,B). In accordance with the increase in
total CD4+ T cells, the percentage of CD4+CXCR5+PD-1+
TFH cells were significantly increased in αSLAMF3-injected
recipient mice (Figure 4C). PD1 expression was not only
increased on the surface of CD4 of TFH cells, we also found
an increase in number and expression of PD1+ CD4+ T cells
in αSLAMF3-injected recipients (Figure S4). Importantly, these
activated CD4+ T cells did not only secrete more IFNγ in
response to administering, but also increased amounts of the
key cytokines IL-4 and IL-21, while IL-17 remained unchanged
(Figures 4E–H). These findings correlate with reports that SLE
patients as well as lupus-prone mice have increased serum
levels of IL-21, IFNγ, and IL-17 (20–23). We conclude that the
high levels of IL-4, IL-21, and IFNγ in cGVHD are further
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FIGURE 2 | Administration of αSLAMF3 induces lupus-related autoantibody responses in the recipients of bm12 CD4+ T cells. 6 × 106 CD4+ T cells isolated from
bm12 female mice were transferred into B6 WT recipients by i.p. injection. The recipients of bm12 CD4+ T cells were injected with anti-SLAMF3 or Isotype IgG1 (200
µg/mouse) on days−1 and 14. Mice were euthanized on day 28. Spleens and serums were analyzed. (A–C) Anti-Chromatin, anti-ssDNA, and anti-dsDNA in the
serum of recipient mice were determined by ELISA. (D) Representative FACS plots showing B220+ IgD−CD138+ plasma cells from the spleens (Left panel).
Percentage of plasma cells in spleen of isotype and αSLAMF3 injected mice (Right panel). (E,F) The indicated recipient mice were sacrificed and spleen were
embedded in optimal cutting temperature compound (OCT) tissue media and frozen on dry ice. Seven-micrometer thick frozen sections were fixed to slides in ice-cold
acetone for 15min. The sections were stained with B220 FITC, GL-7 PE, and CD35 Pacific Blue. Representative confocal images and quantification of the germinal
center sizes are shown. Data represent at least four independent experiments, p-values are as shown.
enhanced by triggering αSLAMF3, which drives the dysregulated
GC reaction.
Selective Increase of the Number of Donor
CD4+CD45.1+ T Cells Upon Administering
αSLAMF3 During cGVHD
In order to distinguish between the role of donor and recipient
T cells in the GC reaction, we crossed bm12 and CD45.1 mice
and subsequently transferred bm12xCD45.1 donor CD4+ T
cells into recipient CD45.2+ B6 WT mice. Fourteen days after
transfer, mice were euthanized and CD4+ T cells were analyzed.
Significantly, only the donor CD4+ T cells (CD4+CD45.1+)
had expanded in αSLAMF3-injected mice, while recipient CD4+
T cells were unaffected (Figures 5A,B). More specifically, we
identified significantly expanded CD45.1+ donor TFH cells in the
recipient mice injected with αSLAMF3 (Figure 5C).
Upon Induction of Chronic GVHD by the
Transfer of bm12 CD4+ Cells Into B6 Mice
Donor Cell Treg and TFR Development Is
Selectively Impaired by αSLAMF3
Regulatory T (Treg) cells have been demonstrated to play vital
roles in suppressing cellular and humoral immune responses,
i.e., by suppressing autoreactive B cell functions and subsequent
autoantibody production (24–26). Of interest, recent studies have
identified a subset of regulatory T cells in the GCs, termed T
follicular regulatory (TFR) cells that suppress TFH andGCB cells
(27). Therefore, we hypothesized that TFR cells may be affected
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FIGURE 3 | Anti-SLAMF3 accelerates GC B cell differentiation initiated by cGVHD. Anti-SLAMF3 or isotype injected bm12 CD4+ T cell transferred WT recipient mice
were analyzed on day 14 when GC reactions peaked. (A) Percentages of B220+CD69+ B cells are as shown. (B) Expression of CD86 on B cells. (C) FAS expression
in non-GC B and GC B cells from isotype and aSLAMF3 injected recipients. (D,E) Representative Flow cytometry plot for GC staining: CD19+GL-7+FAS+ B cells (left
panel), percentages of GC B (Right panel) and numbers of GC B cells in spleen of mice. (F) Representative FACS plots of B220+ IFN-γR+ GC B cells from isotype and
αSLAMF3-injected recipients. (G) The percentage of B220+ IFN-γR+ GC B cells in the spleens of isotype and αSLAMF3-injected recipients. Data represent at least
four independent experiments.
from injections of αSLAMF3. Fourteen days after transfer of
bm12 CD4+ T cells into B6 WT recipients and subsequent 2
injections of αSLAMF3, mice were euthanized and analyzed for
TFR cells at the peak of GC reactions. TFR cells, defined as
CD4+CXCR5+PD-1+FoxP3+ were significantly reduced from
spleen of αSLAMF3-injectedmice as compared to isotype control
(Figures 6A,B). Furthermore, TFRs present in αSLAMF3-
injected mice had significantly higher PD1 expression compared
to isotype control (Figure 6C). This suggests that negative
regulation within the GCs is lost upon αSLAMF3 injections.
As TFR cells originate from Treg precursors (27), we
checked whether SLAMF3 signaling also has negative effect
on Treg differentiation. Similar to the impact on TFR cells,
αSLAMF3-injected recipients exhibited a substantial decrease
in the frequency of CD4+Foxp3+CD25+ T cells compared
with isotype control injected mice (Figures 7A,B). Strikingly,
the impact of anti-SLAMF3 was specific to donor-derived Treg
cells because the administration of αSLAMF3 exerted no effect
on recipient-derived Treg cells (Figure 7C). Together, these
data demonstrate that SLAMF3 signaling not only inhibited
TFR cell differentiation but also of Treg cells, which may
contribute to exacerbated autoimmune responses in αSLAMF3-
injected recipients.
DISCUSSION
In studies of murine autoimmune-like chronic graft vs.-host
disease (cGVHD), B cells are activated by donor CD4+ T
cells to upregulate MHC II and costimulatory molecules.
Acting as efficient APCs, donor B cells further augment
donor the clonal expansion, differentiation, and survival of
pathogenic CD4+ T cells, which drives autoreactivity. Because
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FIGURE 4 | Administering αSLAMF3 increases T cell activation and TFH cell differentiation initiated by cGVHD. Anti-SLAMF3 or isotype injected bm12 CD4+ T cell
transferred B6 WT recipient mice were analyzed on day 14 when GC reactions peaked. (A,B) Percentages of CD4+CD44+CD62lo memory T cells and
CD4+CD69+CD44hi effector T cells in isotype and αSLAMF3 injected mice. (C) Representative Flow cytometry plot showing gating strategy for TFH cells:
CD4+PD-1+CXCR5+ (left panel) Percentages of TFH cells in spleen of αSLAMF3 and isotype injected mice (right panel). (D) Absolute numbers of TFH cells in isotype
and aSLAMF3 injected mice. (E,H) Expression of following cytokines was measured by intracellular staining in CD4+CD45.1+ splenocytes from isotype and
αSLAMF3-injected recipients. Percentages of CD4+ IFN-γ+ T cells, CD4+ IL4+ T cells, CD4+ IL-21+ T cells, and CD4+ IL-17+ T cells are shown.
SLAMF3-deficient mice develop autoantibodies irrespective
of their genetic background, and as development several B
cell subsets, e.g., Marginal zone [MZ] B cells are eliminated
in these mice, we adopted a cGVHD model to investigate the
importance of SLAMF3 signaling in this disease. To this end we
examined the effect of a mouse anti-mouseSLAMF3 monoclonal
antibody on hapten-induced humoral responses and on
autoantibody production in the bm12 CD4+ > B6 transfer model
of cGVHD.
The latter model was chosen because it mirrors a few common
pathways of human disease, e.g., high levels of circulating
anti-nuclear antibodies, concomitantly with large frequencies
of T follicular helper cells (Tfh), germinal center (GC) B
cells, and plasma cells. We previously had shown that by
using lupus—prone B6 mutants in this cGVHD model the
autoantibody production is accelerated. Conversely, specific
monoclonal antibodies, which affect GC formation in mice
that are immunized with foreign antigens, also ameliorate the
generation of anti-nuclear antibodies in this bm12>B6 cGVHD
model (11, 12). As also shown by others, cGVHD can be induced
both by the transfer of bm12 derived CD4+ cells into B6 mice or
by B6-derived CD4+ cells into the co-isogenic bm12 recipients
with equal efficiency (8, 9).
In our analyses of NP-OVA immunizations combines with
administering αSLAMF3, we demonstrate that in response to
foreign antigens, SLAMF3 primarily affects the maturation into
GC B cells, leading to diminished antibody responses. By
contrast, injections of αSLAMF6 in NP-OVA immunized mice,
SLAMF6 signaling affected both B and T cells in the germinal
centers (2).
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FIGURE 5 | Selective increase of the number of donor CD4+CD45.1+ T cells upon administering αSLAMF3 during cGVHD. (A) Representative dot plots of
CD4+CD45.1+ T cells from isotype and αSLAMF3-injected recipients (left panel). The number of CD4+CD45.1+ donor T cells in the spleens of isotype and
αSLAMF3-injected recipients (right panel). (B) The number of CD4+CD45.2+ recipient T cells in the spleens of isotype and αSLAMF3-injected recipients. (C)
Representative FACS plots of CD45.1+ donor TFH cells (left) with percentages of CD45.1+ TFH cells in isotype and αSLAMF3 (right). Data represent at least four
independent experiments.
Precise regulation of TFH cell numbers is critical for optimal
humoral responses, and aberrant expansion of TFH cells is
associated with autoimmune diseases, including lupus (28, 29).
In our system, we found that the administration of αSLAMF3
significantly enhanced proliferation of donor-derived CD4+ T
cells, which lead to profound TFH cell differentiation in GCs.
As a consequence, we observed severe autoimmune phenotypes
in αSLAMF3-injected recipients, which included increased
serum levels of anti-dsDNA, anti-ssDNA, and anti-chromatin
autoantibodies (Figure 1). This was a consequence of enlarged
germinal centers with massive accumulation of GC B cells in
the spleens (Figure 2). Although several molecules, including
CD40L, ICOS, PD-1, and SAP, are known to be involved in TFH
cell differentiation, the transcriptional repressor Bcl6 is found
to be a lineage-defining factor for TFH cells. Bcl6 is necessary
to specify the TFH cell program and overexpression of Bcl6
is sufficient to drive TFH cell differentiation (30). Indeed, the
expression of Bcl6 was markedly increased in αSLAMF3-injected
recipients, but not in isotype control injected recipient mice
(Unpublished observation). Beside BCR signaling, the survival
and selection of GC B cells within GCs are dependent on survival
signals from GC TFH cells. The experiments reported here are
consistent with strong TFH cell differentiation with extensive GC
B cell responses. Recent publications have suggested that B cells
have a cell-intrinsic requirement for expression of CD80 and/or
CD86 for differentiation into GC B cells (31, 32). In accord, we
found increased expression of CD86 in B cells and GC B cells in
αSLAMF3-injected recipient mice.
Interestingly, IFN-γR signals are shown to synergize with
BCR, TLR, and CD40 dependent signal to enhance expression
of the GC master regulator transcription factor Bcl6 (19), which
suggest IFN-γ facilitates autoimmune GC formation by initiating
a GC transcriptional program. Based on these findings by others,
we examined the expression Bcl6 and IFN-γR and found that
GC B cells exhibited increased Bcl6 and IFN-γR. In addition,
we observed higher expression of anti-apoptotic protein Bcl-2 in
αSLAMF3-injected GC B cells (unpublished observation). This
in turn may reduce overall apoptosis of GC B cells and ultimately
result in increased numbers of GC B cells in the GCs. It will be of
interest to determine whether the expression of other members of
the Bcl-2 family, such as Mcl-1, are also increased in αSLAMF3-
injected GC B cells. Thus, it appears that αSLAMF3 may act on
both B and T cell sides during autoimmune GC reactions.
In addition, αSLAMF3 had a pronounced effect on key
cytokines produced during GC reactions. IL-21, IL-4, and
IFN-γ production were significantly elevated in donor-derived
CD4+ T cells of αSLAMF3-injected recipients. Although IL-21
production is restricted to activated CD4T and NKT cells, IL-21
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FIGURE 6 | Anti-SLAMF3 inhibits TFR cell differentiation. (A) Representative gating strategy of TFR cells from spleens of the recipients of bm12 CD4+ T cells:
CD4+CXCR5+PD-1+Foxp3+ (B) Percentages of TFR cells in the spleens of isotype and αSLAMF3-injected mice. (C) Cell surface expression of PD-1 on TFR cells in
the spleens of isotype and αSLAMF3-injected mice. Data represent at least four independent experiments.
FIGURE 7 | Upon induction of chronic GVHD by the transfer of bm12 CD4+ T cells into B6 mice donor cell Treg development is selectively impaired by αSLAMF3. (A)
Representative FACS plots of total CD4+ T and subsequent donor/recipient CD4+CD45.1+ and CD4+CD45.2+, respectively. Of these subsets, Treg population was
determined as CD25+FoxP3+. (B) Percentage of total CD4+CD25+Fox3+Treg cells in the spleens of isotype and αSLAMF3-injected recipients. (C) Percentages of
CD4+CD45.1+CD25+Fox3+ donor Treg (left panel) and CD4+CD45.1−CD25+Fox3+ recipient Treg (right panel) cells in the spleens of isotype and
αSLAMF3-injected recipients.
receptor is expressed on a variety of immune cells (33, 34). IL-
21 promotes the differentiation and expansion of TFH cells,
regulates B cell proliferation and survival, GC formation, and
plasma cell differentiation (35–37). Furthermore, IL-21 has an
important role in regulating T cell-dependent B cell responses,
partly in cooperation with IL-4 (38). IL-21 is markedly elevated
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in autoimmune-prone mice and lupus severity is diminished in
the absence of IL-21 or IL-21R signaling (21, 39). Besides IL-
21, IFN-γ also contributes to lupus in both human and murine
models. The increased serum IFN-γ levels are associated with
disease activity and the inhibition of IFN-γ expression prevents
the development of murine lupus (40, 41). Thus, the combined
alteration of IL-21, IFN-γ, and IL-4 production in αSLAMF3-
injected recipients may play an important role in higher GC
formation and autoantibody production.
We were surprised to find that αSLAMF3 injections resulted
in reduced numbers of Treg cells in the recipients of bm12
CD4+ T cells. The pivotal roles of Treg cells in the development
and maintenance of immune self-tolerance have been well
documented (42). It was thought that Treg cells functioned
as immuno-suppressors in allogeneic immune responses and
in autoimmune responses. In this study, recipient Treg cells
does not seem to play a major role in suppressing lupus-like
phenotype as similar numbers of Treg cells were differentiated
in both αSLAMF3 and isotype-injected recipient mice. In
contrast, donor-derived Treg cells were significantly reduced
after αSLAMF3 injections. Thus, these data suggest that
αSLAMF3 specifically limits proliferation of donor-derived Treg
cells, but have minimal effect on proliferation of host Treg
cells. Perhaps the most striking finding in our studies was the
reduced differentiation of donor-derived TFR cells. TFR cells
are another subset of CD4+ T cells in the GCs (43, 44). TFR
cells share phenotypic characteristics with TFH but are derived
from suppressive FoxP3+ Treg cells. Within the GC, TFR cells
inhibit GC formation and restrict the autoimmune responses
(45). Our findings indicate that the reduced number of TFR
cells that leads to reduced suppression on TFH cells in the
GCs leads to increased autoantibody production in αSLAMF3-
injected recipients. Although the suppressive capacity of TFR
cells is not examined, the higher expression of PD-1 on TFR cells
indirectly suggest there may be reduced suppressive functions
in αSLAMF3-injected recipients. Further work is needed to
understand how PD-1 expression is regulated in vivo by SLAMF3
signaling. However, the increased expression of PD-1 on TFR
cells might partly contribute to the reduced numbers of TFR
cells in αSLAMF3-injected recipients. This idea is supported by
previous observations that mice deficient in PD-1 have increased
numbers of TFR cells with enhanced suppressive capacity
(46). Collectively, impaired Treg and TFR compartments could
enhance TFH activity, resulting in the expansion of autoreactive
B cells and autoantibody production.
In the cGVHD model, the key cellular mechanism that
results in the loss of B cell tolerance is the interaction of
donor CD4+ T cells with MHC class II on host B cell
surface. During T-B cell interactions, allogeneic donor CD4+
T cells provide the abnormal T cell help to host B cells
that appears to have functional consequences different from
what occurs in spontaneous model. Our results suggested that
αSLAMF3 influences the development of cGVHD through
regulating TFR/Treg cell ratios, as agonist αSLAMF3 induces
hyperactivation of activated donor CD4+ T cells. However, how
αSLAMF3 has a pronounced effect on the donor T differentiation
remains unclear. Donor T cells have classically been considered
the main effector cells, but host APCs cross-present host auto-
antigens to donor T cells, which will be activated and start
proliferating. Because SLAMF3 is expressed on both T cells and
APCs, triggering the receptor on either on T cells or APCs may
induce co-stimulatory signaling, Although Treg cell adoptive
therapy is showing potential as a treatment of cGVHD patients
(47), generating sufficient Treg cells remains a challenge.
In summary, the dual activity of SLAMF3 signaling as
inhibitory or activating, depending on the setting of the immune
response, suggests that SLAMF3 should be further investigated as
a target in a disease dependent manner in humans.
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